Kimberly A. Mcbennett

Palliative Medicine

11100 Euclid Ave
Cleveland, OH 44106

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Utilization of Des-Gamma-Carboxy-Prothrombin in Estimating Vitamin K Status in People With Cystic Fibrosis: A Single Center Retrospective Review.

Utilization of Des-Gamma-Carboxy-Prothrombin in Estimating Vitamin K Status in People With Cystic Fibrosis: A Single Center Retrospective Review.

Journal: Pediatric pulmonology

Published: January 17, 2026

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.

Journal: Annals of the American Thoracic Society

Published: October 03, 2025

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.

Journal: Annals of the American Thoracic Society

Published: July 28, 2025

Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index.

Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index.

Journal: Pediatric pulmonology

Published: August 12, 2023

Lung T1 MRI assessments in children with mild cystic fibrosis lung disease.

Lung T1 MRI assessments in children with mild cystic fibrosis lung disease.

Journal: Pediatric pulmonology

Published: June 16, 2023

Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study.

Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 09, 2023

Toward a Broader Understanding of Cystic Fibrosis Epidemiology and Its Impact on Clinical Manifestations.

Toward a Broader Understanding of Cystic Fibrosis Epidemiology and Its Impact on Clinical Manifestations.

Journal: Clinics in chest medicine

Published: November 07, 2022

Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.

Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.

Journal: The New England journal of medicine

Published: August 26, 2021

Increasing life expectancy in cystic fibrosis: Advances and challenges.

Increasing life expectancy in cystic fibrosis: Advances and challenges.

Journal: Pediatric pulmonology

Published: July 15, 2021

Rapid B1-Insensitive MR Fingerprinting for Quantitative Kidney Imaging.

Rapid B1-Insensitive MR Fingerprinting for Quantitative Kidney Imaging.

Journal: Radiology

Published: June 08, 2021

Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapies.

Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapies.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: April 01, 2021

Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients.

Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients.

Journal: World journal of hepatology

Published: September 04, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026